课题基金 / 基金详情

ACTG 366: PATIENTS W/ RAPIDLY PROGRESSING ADVANCED DISEASE: "RAD-1"

ACTG 366: PATIENTS W/ RAPIDLY PROGRESSING ADVANCED DISEASE: "RAD-1"
ACTG 366：患有快速进展的晚期疾病的患者：“RAD-1”
批准号：
6308596
负责人：
ANN PETRU
金额：
$1.75万
依托单位：
UNIVERSITY OF CALIFORNIA, SAN FRANCISCO
依托单位国家：
美国
项目类别：
财政年份：
1999
资助国家：
美国
项目状态：
已结题
起止时间：
1999-12-01 至 2000-11-30
来源：
https://reporter.nih.gov/project-details/6308596
关键词：
AIDS /HIV neuropathy AIDS therapy adolescence (12-20) age difference child (0-11) clinical research combination chemotherapy drug screening /evaluation human subject human therapy evaluation pediatric AIDS pharmacokinetics virus load

项目摘要

项目成果

ANN PETRU的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
This study offers advanced combinations of drugs to children with advanced disease, and the choices of agents will depend upon their prior drug experiences. Objectives are to evaluate decreses in viral load and durations of response; safety and tolerance by age; routine and steady state pharmacokinetcs by age, including CNS disease evaluation and virus and drug penetration into the CSF. This study includes at least 3 evaluations of each of the following: MRI, neuropsychological/neurodevelopmental (NP/ND) assessments, spinal taps, all in <2 year-old patients. Inclusion criteria are 6 mos-20 years old with >8 weeks of prior therapy, growth failure, CD4 <15%, >50% drop in CD4% or CD4 number, viral load over 100,000 or NP/ND progression of disease. Children must be able to receive at least 2 new agents.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
LATE OUTCOMES FOR TREATMENT OF HIV INFECTION
EFFECT OF ANTIRETROVIRAL THERAPY ON BODY COMPOSITION IN CHILDRENPACTG 1010
ACTG P1024
ACTG P1024 EVALUATION OF THE IMMUNOGENICITY OF PNEUMOCOCCAL CONJUGATE VACCINE...
海外基金